Highlight
– Tirzepatide significantly lowers the risk of cardiovascular death or worsening heart failure events in obese patients with HFpEF.
– The drug’s benefits on heart failure outcomes and quality of life are similar regardless of the presence of type 2 diabetes.
– Weight loss is less pronounced in patients with type 2 diabetes; however, improvements in visceral fat and left ventricular mass are comparable.
– These findings challenge the assumption that weight loss magnitude directly predicts cardiovascular benefits from incretin-based therapies in heart failure.
